Alpha Crest Capital Management LLC Glaukos Corp Transaction History

Alpha Crest Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $180,006 - $224,777	3,843 New	3,843 $205,000
Q2 2022 Aug 11, 2022	SELL	$34.86 - $63.77 $365,890 - $669,329	-10,496 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$44.33 - $57.82 $904,553 - $1.18 Million	-20,405 Reduced 66.03%	10,496 $607,000
Q4 2021 Feb 09, 2022	BUY	$40.27 - $56.99 $703,436 - $995,501	17,468 Added 130.04%	30,901 $1.37 Million
Q3 2021 Nov 10, 2021	BUY	$47.43 - $84.23 $516,417 - $917,096	10,888 Added 427.82%	13,433 $647,000
Q2 2021 Aug 12, 2021	SELL	$73.06 - $97.7 $165,407 - $221,192	-2,264 Reduced 47.08%	2,545 $216,000
Q1 2021 May 13, 2021	BUY	$70.43 - $97.42 $338,697 - $468,492	4,809 New	4,809 $404,000
Q4 2020 Feb 12, 2021	SELL	$48.9 - $75.26 $329,683 - $507,402	-6,742 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$37.23 - $50.97 $12,732 - $17,431	342 Added 5.34%	6,742 $334,000
Q2 2020 Aug 12, 2020	SELL	$28.78 - $46.83 $60,438 - $98,343	-2,100 Reduced 24.71%	6,400 $246,000
Q1 2020 May 13, 2020	BUY	$25.53 - $70.14 $217,005 - $596,190	8,500 New	8,500 $262,000

345

46.7M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.63B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.